In yesterday’s Wall Street session, Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares traded at $25.70, down -2.91% from the previous session.
As of this writing, 3 analysts cover Eagle Pharmaceuticals Inc. (NASDAQ:EGRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $33.00 and a low of $31.00, we find $32.00. Given the previous closing price of $26.47, this indicates a potential upside of 20.89 percent. EGRX stock price is now -15.07% away from the 50-day moving average and -25.15% away from the 200-day moving average. The market capitalization of the company currently stands at $344.64M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
There are 2 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $32.00 as their price target over the next twelve months.
, while ‘Piper Jaffray’ rates the stock as ‘Neutral’.
In other news, Edlin Richard A., Director sold 6,800 shares of the company’s stock on Sep 06. The stock was sold for $210,732 at an average price of $30.99. Upon completion of the transaction, the Director now directly owns 22,600 shares in the company, valued at $0.58 million. Insiders disposed of 20,771 shares of company stock worth roughly $0.53 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EGRX stock. A new stake in Eagle Pharmaceuticals Inc. shares was purchased by LSV ASSET MANAGEMENT during the first quarter worth $3,891,000. BANK OF NOVA SCOTIA invested $2,192,000 in shares of EGRX during the first quarter. In the first quarter, HRT FINANCIAL LP acquired a new stake in Eagle Pharmaceuticals Inc. valued at approximately $1,569,000. LOS ANGELES CAPITAL MANAGEMENT LLC acquired a new stake in EGRX for approximately $1,086,000. JACKSON CREEK INVESTMENT ADVISORS LLC purchased a new stake in EGRX valued at around $647,000 in the second quarter. In total, there are 234 active investors with 89.10% ownership of the company’s stock.
Friday morning saw Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) opened at $26.11. During the past 12 months, Eagle Pharmaceuticals Inc. has had a low of $23.87 and a high of $52.22. As of last week, the company has a debt-to-equity ratio of 0.26, a current ratio of 1.50, and a quick ratio of 1.00. The fifty day moving average price for EGRX is $30.17 and a two-hundred day moving average price translates $34.23 for the stock.
The latest earnings results from Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) was released for Sep, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $1.12, beating analysts’ expectations of $0.91 by 0.21. This compares to -$0.47 EPS in the same period last year. The net profit margin was 7.20% and return on equity was 10.60% for EGRX. The company reported revenue of $60.7 million for the quarter, compared to $42.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 43.43 percent. For the current quarter, analysts expect EGRX to generate $64.26M in revenue.
Eagle Pharmaceuticals Inc.(EGRX) Company Profile
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
